Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Oncotarget
|
April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes
Anne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial
Elisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2019
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
Sébastien Couraud, Fabrice Barlesi, Clara Fontaine-Deraluelle, et al.
JTO Clinical and Research Reports
|
December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Valérie Gounant, Laurent Greillier, Céline Mascaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Alexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Simon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Thomas Pierre Walter, Julien Mazieres, Josiane Otto, et al.
Lancet (London, England)
|
January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Oncotarget
|
April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes
Anne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 8, 2020
Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial
Elisabeth Quoix, Clarisse Audigier-Valette, Armelle Lavolé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2019
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2019
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
Sébastien Couraud, Fabrice Barlesi, Clara Fontaine-Deraluelle, et al.
JTO Clinical and Research Reports
|
December 31, 2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Valérie Gounant, Laurent Greillier, Céline Mascaux, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2020
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study
Alexis B Cortot, Clarisse Audigier-Valette, Olivier Molinier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort
Simon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2026
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Thomas Pierre Walter, Julien Mazieres, Josiane Otto, et al.
Lancet (London, England)
|
January 19, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi, Julien Mazieres, Jean-Philippe Merlio, et al.
Page
of 5